Press Release

Flatiron Health Announces Research to be Presented at European Society for Medical Oncology Congress 2019

NEW YORK, NY, September 26, 2019

Flatiron Health today announced 13 abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2019, which will be held September 27 – October 1, 2019, in Barcelona, Spain. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s high-quality, real-world oncology datasets. Collectively, these research presentations highlight the various applications of real-world evidence, enabling deep clinical insights to better understand the use of biomarkers, comparative effectiveness of therapies and outcomes in routine clinical care. 

Presentations include collaborator research by the U.S. Food & Drug Administration’s Oncology Center of Excellence, Huntsman Cancer Institute, Yale Cancer Center, Bayer, Bristol-Myers Squibb, Celgene, Merck, Pfizer, Roche/Genentech and Foundation Medicine.

The presentation schedule and links to abstracts can be found below.

Poster Discussion

Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset

First Author: Daniel Backenroth (Flatiron Health)
Date/Time: September 29 — 08:45 – 09:45
Presentation: #1877PD

Poster Sessions

Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)

First Author: Denis Talbot (University of Oxford)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1497P

Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States

First Author: David D. Stenehjem (University of Minnesota)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1498P

Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) in US clinical practice

First Author: Matthew G. Krebs (The Christie NHS Foundation Trust)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1546P

Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers

First Author: Matthew G. Krebs (The Christie NHS Foundation Trust)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1551P

Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)

First Author: Aaron B. Cohen (Flatiron Health)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1558P

Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)

First Author: Xinran Ma (Flatiron Health)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #1581P

Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis

First Author: Mylin Torres (Winship Cancer Institute, Emory University School of Medicine)
Date/Time: September 28 — 12:00 – 13:00
Presentation: #327P

Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices

First Author: Rachel M. Layman (Pfizer)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #329P

Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

First Author: Thibaut Sanglier (Roche)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #356P

Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

First Author: Xiaolong Jiao (Bayer)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #102P

Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies

First Author: Aracelis Z. Torres (Flatiron Health)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #1290P

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma

First Author: Justin Moser (Huntsman Cancer Institute)
Date/Time: September 30 — 12:00 – 13:00
Presentation: #1346P